Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress
June 21 2022 - 8:30AM
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of therapeutics designed to activate the immune response
to cancers and infections, today announced the Company will host a
hybrid webcast to discuss botensilimab/balstilimab combination data
in microsatellite stable colorectal cancer (MSS-CRC) presented
earlier that day in a late-breaking oral presentation at the ESMO
World Congress on Gastrointestinal Cancer in Barcelona, Spain.
The webcast will take place on Wednesday, June 29 at 10:00 AM
EST (4:00 PM local time) and will include the following
speakers:
- Steven O’Day, M.D., Agenus’ Chief
Medical Officer,
- Dr. Anthony El-Khoueiry, M.D., Phase
I Program Director at the USC Norris Comprehensive Cancer Center,
Keck Medicine of USC,
- Dr. Manuel Hidalgo, Chief of the
Division of Hematology and Medical Oncology at Weill Cornell
Medicine/NewYork-Presbyterian Hospital, and
- Dr. Heinz-Josef Lenz, M.D.,
Professor of Medicine and J. Terrence Lanni Chair in
Gastrointestinal Cancer Research, Keck Medicine of USC
Formal remarks will be followed by a Q&A session. For those
attending in person, the webcast will take place at:
AC Hotel by Marriott Barcelona ForumGracia Room (3rd Fl.)Paseo
Taulat 278Barcelona, Spain, 08019
Registration for the webcast can be accessed on the Investors
section of the Agenus website at investor.agenusbio.com, as well as
here. Following the webcast, an archived version will also be
available on the website.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its subsidiary MiNK
Therapeutics), and adjuvants (through its subsidiary SaponiQx). The
Company is equipped with a suite of antibody discovery platforms
and a state-of-the-art GMP manufacturing facility with the capacity
to support clinical programs. Agenus is headquartered in Lexington,
MA. For more information, please visit www.agenusbio.com and our
Twitter handle @agenus_bio. Information that may be important to
investors will be routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements relating to our technologies, therapeutic candidates,
and capabilities, for instance, statements regarding therapeutic
benefit and efficacy, mechanism of action, potency, durability, and
safety profile of our therapeutic candidates, both alone and in
combination with each other and/or other agents; statements
regarding future plans, including research, clinical, regulatory,
and commercialization plans; and any other statements containing
the words "may," "believes," "expects," "anticipates," "hopes,"
"intends," "plans," "will" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors
section of our most recent Quarterly Report on Form 10-Q or Annual
Report on Form 10-K filed with the Securities and Exchange
Commission and available on our website: www.agenusbio.com. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
Contact
Ethan Lovell339-927-1763ethan.lovell@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024